2023
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Redman R, Stokes W, Rudra S, Mell L, Sacco A, Spencer S, Nabell L, Yao M, Cury F, Mitchell D, Jones C, Firat S, Contessa J, Galloway T, Currey A, Harris J, Curran W, Le Q. Radiotherapy Plus Cisplatin With or Without Lapatinib for Non–Human Papillomavirus Head and Neck Carcinoma. JAMA Oncology 2023, 9: 1565-1573. PMID: 37768670, PMCID: PMC10540060, DOI: 10.1001/jamaoncol.2023.3809.Peer-Reviewed Original ResearchConceptsProgression-free survivalAdverse event ratesOverall survivalStage IIIClinical trialsAcute adverse event ratesProgression-free survival ratesEnd pointEvent ratesAnti-epidermal growth factor receptor (EGFR) antibodiesBenefit of chemoradiotherapyZubrod performance statusPrimary end pointSecondary end pointsCycles of cisplatinAddition of lapatinibEGFR antibody therapyGrowth factor receptor antibodyLog-rank testDual EGFRPlus CisplatinFrontline therapyPerformance statusAntibody therapyNeck carcinoma
2021
TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Mell L, Spencer S, Stokes W, Yao M, Mitchell D, Harris J, Curran W, Le Q. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal Of Clinical Oncology 2021, 39: 6014-6014. DOI: 10.1200/jco.2021.39.15_suppl.6014.Peer-Reviewed Original ResearchProgression-free survivalPhase II trialOverall survivalStage IIIII trialArm AGrade 3Treatment-related grade 3Randomized phase II trialFinal analysisEffects of chemoradiationBaseline patient characteristicsDays of therapyAdverse event ratesSurvival of patientsCycles of CDDPLog-rank testDual EGFRA vs BMucositis ratesRash ratesPFS ratePrimary endpointSecondary endpointsFrontline therapyMeta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, Burtness B, Ghi MG, Cohen EEW, Grau C, Wolf G, Hitt R, Corvò R, Budach V, Kumar S, Laskar SG, Mazeron JJ, Zhong LP, Dobrowsky W, Ghadjar P, Fallai C, Zakotnik B, Sharma A, Bensadoun RJ, Redda M, Racadot S, Fountzilas G, Brizel D, Rovea P, Argiris A, Nagy ZT, Lee JW, Fortpied C, Harris J, Bourhis J, Aupérin A, Blanchard P, Pignon JP, Group M, Adelstein D, Alfonsi M, Belkacemi Y, Bar-Ad V, Bernier J, Bratland Å, Calais G, Campbell B, Caudell J, Chabaud S, Chamorey E, Chaukar D, Choi K, Choussy O, Collette L, Cruz J, Dani C, Dauzier E, Forastiere A, Garaud P, Gregoire V, Hackshaw A, Haddad E, Haffty B, Hansen A, Hayoz S, Horiot J, Jeremic B, Karrison T, Langendijk J, Lapeyre M, Lartigau E, Leong T, Le Q, Lee P, Lewin F, Lin A, Lopes A, Mehta S, Moon J, Moyal E, Occéan B, Olmi P, Orecchia R, O'Sullivan B, Overgaard J, Petit C, Quon H, Sanguineti G, Satar T, Simes J, Simon C, Sire C, Staar S, Stromberger C, Strojan P, Temam S, Thomson D, Timochenko A, Torri V, Tseroni V, Vermorken J, Vokes E, Waldron J, Wernecke K, Widder J, Zackrisson B. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiotherapy And Oncology 2021, 156: 281-293. PMID: 33515668, PMCID: PMC8386522, DOI: 10.1016/j.radonc.2021.01.013.Peer-Reviewed Original ResearchConceptsLoco-regional treatmentConcomitant CTConcomitant chemotherapyOverall survivalNeck cancerNon-metastatic headPoor performance statusSquamous cell headIndividual patient dataNon-metastatic carcinomasAddition of inductionFixed-effects modelPerformance statusPatient ageDistant metastasisRandomized trialsMain endpointCell headStage IIIMeta-AnalysisPatientsChemotherapyPatient dataTrialsCancer
2010
Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer
Turaka A, Li T, Nicolaou N, Lango MN, Burtness B, Horwitz EM, Ridge JA, Feigenberg SJ. Use of a Conventional Low Neck Field (LNF) and Intensity-Modulated Radiotherapy (IMRT): No Clinical Detriment of IMRT to an Anterior LNF During the Treatment of Head-and Neck-Cancer. International Journal Of Radiation Oncology • Biology • Physics 2010, 79: 65-70. PMID: 20385457, PMCID: PMC3339153, DOI: 10.1016/j.ijrobp.2009.10.034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Squamous CellChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesGastrostomyHead and Neck NeoplasmsHumansLinear ModelsLymph Node ExcisionMaleMiddle AgedRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesTreatment FailureConceptsIntensity-modulated radiotherapyLow-neck fieldLower neckDisease-free survival ratesPercutaneous endoscopic gastrostomy tubeNeck fieldSingle-institution studySquamous cell carcinomaLog-rank testTreatment of headAnterior photon fieldAnterior low-neck fieldClinical detrimentCurative intentMedian ageClinical outcomesGastrostomy tubeNeck diseasePEG tubeCell carcinomaNeck cancerPhysician preferenceRegional failureStage IIIPatients